il-6
Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |||
| il-6 [2026/08/31 10:50] – [IL-6 blocking agents] gary1 | il-6 [2026/08/31 10:51] (current) – [IL-6 blocking agents] gary1 | ||
|---|---|---|---|
| Line 142: | Line 142: | ||
| * **pacibekitug** | * **pacibekitug** | ||
| * long acting anti-interleukin-6 monoclonal antibody | * long acting anti-interleukin-6 monoclonal antibody | ||
| - | * in the TRANQUILITY phase 2 study, it reduced 180 day hsCRP levels by 76-89% compared with control and was generally well tolerated(([[https:// | + | * in the TRANQUILITY phase 2 study, it reduced 180 day hsCRP levels by 76-89% compared with 7% increase in the control |
| * **baricitinib** | * **baricitinib** | ||
| * JAK1/JAK2 inhibitor used to Rx [[psoriasis]] | * JAK1/JAK2 inhibitor used to Rx [[psoriasis]] | ||
il-6.txt · Last modified: 2026/08/31 10:51 by gary1